Citations

Clear

2391 citation(s) found for "Ma, Lin".

Depletion of Zebrafish Titin Reduces Cardiac Contractility by Disrupting the Assembly of Z-Discs and A-Bands
Seeley, Michael, Huang, Wei , Chen, Zhenyue , Wolff, William Oscar, Lin, Xueying , Xu, Xiaolei

Mayo Clinic

Circulation Research | December 15, 2006 | Volume: 100 | Issue: 2 | Pages: 238-245

10.1161/01.res.0000255758.69821.b5 | PMID 17170364 Get It

The genetic study of titin has been notoriously difficult because of its size and complicated alternative splicing routes. Here, we have used zebrafish as an animal model to investigate the functions of individual titin isoforms. We identified 2 titin orthologs in zebrafish, ttna and ttnb , and annotated the full-length genomic sequences for both genes. We found that ttna , but not ttnb , is required for sarcomere assembly in the heart as well as the subsequent establishment of cardiac contractility. In fact, ttna is the earliest sarcomeric mRNA that is expressed in the heart, which makes it an early molecular marker for cardiomyocyte differentiation. Surprisingly, ttna is required for later steps of sarcomere assembly, including the assembly of Z-discs and A-bands, but not for early steps such as the assembly of Z-bodies and nonstriated myosin filaments. Reduction of individual titin isoforms in vivo using morpholino-modified antisense oligonucleotides indicated that (1) both N2B exon–containing and N2A exon–containing isoforms of ttna are required for sarcomere assembly in the heart; (2) N2A exon–containing isoforms of both ttna and ttnb are required for sarcomere assembly in the somites; and (3) the N2B exon–containing isoforms of ttnb are expressed later than other titin isoforms and are probably involved in modulating their expression; however, these isoforms of ttnb are not required for sarcomere assembly. Collectively, our results reveal distinct functions of different titin isoforms and suggest that various phenotypes in “titinopathies” may be attributable to the disruption of different titin isoforms.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Yazan, Ngo, Hai T., Runnels, Judith, Leleu, Xavier , Singha, Ujjal K. , Pitsillides, Costas, Spencer, Joel A. , Kimlinger, Teresa K. , Jia, Xiaoying , Lu, Ganwei, Timm, Michael, Côté, Daniel , Veilleux, Israël , Hedin, Karen E. , Roodman, G. David, Kung, Andrew L. , Hideshima, Teru , Lin, Charles P. , Ghobrial, Joanna M. , Kumar, Ashok , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M.

Mayo Clinic

Blood | November 22, 2006 | Volume: 109 | Issue: 7 | Pages: 2708-2717

10.1182/blood-2006-07-035857 | PMID 17119115 Get It

Abstract The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and its receptor CXCR4 on the migration and homing of MM cells. We demonstrated that CXCR4 is differentially expressed at high levels in the peripheral blood and is down-regulated in the bone marrow in response to high levels of SDF-1. SDF-1 induced motility, internalization, and cytoskeletal rearrangement in MM cells evidenced by confocal microscopy. The specific CXCR4 inhibitor AMD3100 and the anti-CXCR4 antibody MAB171 inhibited the migration of MM cells in vitro. CXCR4 knockdown experiments demonstrated that SDF-1–dependent migration was regulated by the PI3K and ERK/MAPK pathways but not by p38 MAPK. In addition, we demonstrated that AMD3100 inhibited the homing of MM cells to the bone marrow niches using in vivo flow cytometry, in vivo confocal microscopy, and whole body bioluminescence imaging. This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking.
Characterization of "Peak E," a Novel Amino Acid Associated with Eosinophilia-Myalgia Syndrome
Mayeno, Arthur N., Foote, Christopher S., Loegering, David A., Ames, Matthew M. , Hedberg, Craig W. , Gleich, Gerald J. , Lin, Feng

Mayo Clinic

Science | October 5, 2006 | Volume: 250 | Issue: 4988 | Pages: 1707-1708

10.1126/science.2270484 | PMID 2270484 Get It

Epidemiologic studies strongly associate eosinophilia-myalgia syndrome (EMS) with ingestion of tryptophan containing a contaminant ("peak E"). Prior reports have suggested that peak E is the di-tryptophan Nα-animal of acetaldehyde. Spectral and chemical studies now demonstrate that peak E is 1,1′-ethylidenebis[tryptophan]. This novel amino acid may be the etiological agent responsible for EMS, or it may be a marker of a still unidentified causal agent.
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Geyer, Susan M. , Call, Timothy G. , Jelinek, Diane F., Tschumper, Renee C. , Bone, Nancy D., Dewald, Gordon W., Lin, Thomas S., Heerema, Nyla A. , Smith, Lisa , Grever, Michael R., Byrd, John C., Byrd, John C. , Kay, Neil E. , Shanafelt, Tait D. , Zent, Clive S. , Byrd, John C

Mayo Clinic

Blood | September 29, 2006 | Volume: 109 | Issue: 2 | Pages: 405-411

10.1182/blood-2006-07-033274 | PMID 17008537 Get It

AbstractBuilding on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m2), cyclophosphamide (600 mg/m2), and rituximab (375 mg/m2) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were high Rai risk, 71% were nonmutated for the immunoglobulin heavy-chain variable region gene, 34% were CD38+, and 34% were ZAP-70+. Thirty patients (52%) had one anomaly detected by fluorescence in situ (FISH) hybridization, and 21 (36%) had complex FISH defects. Thirty-eight patients (58%) had grade 3+ hematologic toxicity but minimal transfusion needs and no major infections. Responses occurred in 58 patients (91%), with 26 (41%) complete responses (CRs), 14 (22%) nodular partial responses (nodular PRs), and 18 (28%) partial responses (PRs). Many patients with a CR also lacked evidence of minimal residual disease by 2-color flow cytometry. Examination of prognostic factors demonstrated poor response in the 3 patients with del(17p). In contrast, we found this regimen was equally effective in young versus older (> 70 years) patients and in del(11q22.3) versus other favorable prognostic factors. Thus, this novel regimen of pentostatin, cyclophosphamide, and rituximab for previously untreated patients with CLL demonstrated significant clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in some, and modest toxicity.
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
Yu, Chunrong, Friday, Bret B., Lai, Jin-Ping, Yang, Lin , Carter, Christopher A., Roberts, Lewis R. , Adjei, Alex A. , Sarkaria, Jann N. , Kay, Neil E. , Kaufmann, Scott H. , Roberts, Lewis R

Mayo Clinic

Molecular Cancer Therapeutics | September 19, 2006 | Volume: 5 | Issue: 9 | Pages: 2378-2387

10.1158/1535-7163.mct-06-0235 | PMID 16985072 Get It

Abstract This study was undertaken to characterize preclinical cytotoxic interactions for human malignancies between the multikinase inhibitor sorafenib (BAY 43-9006) and proteasome inhibitors bortezomib or MG132. Multiple tumor cell lines of varying histiotypes, including A549 (lung adenocarcinoma), 786-O (renal cell carcinoma), HeLa (cervical carcinoma), MDA-MB-231 (breast), K562 (chronic myelogenous leukemia), Jurkat (acute T-cell leukemia), MEC-2 (B-chronic lymphocytic leukemia), and U251 and D37 (glioma), as well as cells derived from primary human glioma tumors that are likely a more clinically relevant model were treated with sorafenib or bortezomib alone or in combination. Sorafenib and bortezomib synergistically induced a marked increase in mitochondrial injury and apoptosis, reflected by cytochrome c release, caspase-3 cleavage, and poly(ADP-ribose) polymerase degradation in a broad range of solid tumor and leukemia cell lines. These findings were accompanied by several biochemical changes, including decreased phosphorylation of vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor-β, and Akt and increased phosphorylation of stress-related c-Jun NH2-terminal kinase (JNK). Inhibition of Akt was required for synergism, as a constitutively active Akt protected cells against apoptosis induced by the combination. Alternatively, the JNK inhibitor SP600125 could also protect cells from apoptosis induced by the combination, indicating that both inhibition of Akt and activation of JNK were required for the synergism. These findings show that sorafenib interacts synergistically with bortezomib to induce apoptosis in a broad spectrum of neoplastic cell lines and show an important role for the Akt and JNK pathways in mediating synergism. Further clinical development of this combination seems warranted. [Mol Cancer Ther 2006;5(9):2378–87]
P1–102: Apoptosis of oligodendrocytes in an inducible model of tauopathy
Zehr, Cindy, Lin, Wenglang, Hutton, Michael , Lewis, Jada , Knight, Joshua A. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_5 | Pages: No page available

10.1016/j.jalz.2006.05.478 Get It

Tearing without pain after trigeminal root section for cluster headache
Lin, Helen, Dodick, David W.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 65 | Issue: 10 | Pages: 1650-1651

10.1212/01.wnl.0000184522.12998.11 | PMID 16301498 Get It

Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population
Joshi, Nina, Johnson, Laura Lee , Wei, Wenqiang , Abnet, Christian C. , Dong, Zhiwei , Hawk, Ernest T. , Qiao, You‐Lin , Taylor, Philip R. , Limburg, Paul J. , Dawsey, Sanford M. , Kirsch, Ilan R. , Abnet, Christian C

Mayo Clinic

Cancer Research | July 6, 2006 | Volume: 66 | Issue: 13 | Pages: 6851-6860

10.1158/0008-5472.can-06-0662 | PMID 16818663 Get It

AbstractA randomized, double-blinded, placebo-controlled 2 × 2 factorial chemoprevention trial was conducted in Linxian, China to assess the effects of selenomethionine and celecoxib on the natural history of esophageal squamous dysplasia. Results from this study indicated that asymptomatic adults with mild dysplasia were more likely to show an improvement when treated with selenomethionine compared with placebo (P = 0.02). Prompted by this finding, we examined the molecular profiles associated with regression and progression of dysplastic lesions in normal mucosa from 29 individuals, a subset of the Linxian cohort, using the Affymetrix U133A chip. Twenty differentially expressed genes were associated with regression and 129 were associated with progression when we compared the change in gene expression over time. Genes associated with immune response (n = 15), cell cycle (n = 15), metabolism (n = 15), calcium transport or calcium ion activity (n = 10), regulation of transcription (n = 9), signal transduction (n = 7), cytoskeleton and microtubules (n = 5), nucleotide processing and biosynthesis (n = 4), G-coupled signaling (n = 4), and apoptosis (n = 3) were present in the list of 149 genes. Using the Expression Analysis Systematic Explorer pathway analysis program, only the immune response pathway was significantly overrepresented among these 149 genes. Individuals whose lesions regressed seemed to have higher expression of genes associated with immune stimulation, such as antigen presentation, survival of T cells, and T-cell activation (HLA-DRA, HLA-DPA1, HLA-DBQ1, CD58, and FCER1A). In contrast, individuals whose lesions progressed had higher expression of genes involved in immune suppression and inflammation (CNR2, NFATC4, NFRKB, MBP, INHBB, CMKLR1, CRP, ORMS, SERPINA7, and SERPINA1). These data suggest that local and systemic immune responses may influence the natural history of esophageal squamous dysplasia. (Cancer Res 2006; 66(13): 6851-60)
Mutagen Sensitivity Has High Heritability: Evidence from a Twin Study
Wu, Xifeng , Spitz, Margaret R., Amos, Christopher I., Lin, Jie , Shao, Lina , Gu, Jian , Benowitz, Neal L. , Shields, Peter G. , Swan, Gary E. , Andrade, Mariza de , Gu, Jian

Mayo Clinic

Cancer Research | June 15, 2006 | Volume: 66 | Issue: 12 | Pages: 5993-5996

10.1158/0008-5472.can-06-1007 | PMID 16778168 Get It

Abstract Despite numerous studies showing that mutagen sensitivity is a cancer predisposition factor, the heritability of mutagen sensitivity has not been clearly established. In this report, we used a classic twin study design to examine the role of genetic and environmental factors on the mutagen sensitivity phenotype. Mutagen sensitivity was measured in peripheral blood lymphocytes from 460 individuals [148 pairs of monozygotic (MZ) twins, 57 pairs of dizygotic (DZ) twins, and 50 siblings]. The intraclass correlation coefficients were all significantly higher in MZ twins than in dizygotes (DZ pairs and MZ-sibling pairs combined) for sensitivity to four different mutagen challenges. Applying biometric genetic modeling, we calculated a genetic heritability of 40.7%, 48.0%, 62.5%, and 58.8% for bleomycin, benzo[a]pyrene diol epoxide, γ-radiation, and 4-nitroquinoline-1-oxide sensitivity, respectively. This study provides the strongest and most direct evidence that mutagen sensitivity is highly heritable, thereby validating the use of mutagen sensitivity as a cancer susceptibility factor. (Cancer Res 2006; 66(12): 5993-6)
Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population
Joshi, Nina, Johnson, Laura Lee , Wei, Wenqiang , Abnet, Christian C. , Dong, Zhi-Wei, Hawk, Ernest T. , Qiao, You‐Lin , Taylor, Philip R. , Limburg, Paul J. , Dawsey, Sanford M. , Kirsch, Ilan R. , Abnet, Christian C

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 15, 2006 | Volume: 15 | Issue: 5 | Pages: 1046-1047

10.1158/1055-9965.epi-06-0135 | PMID 16702392 Get It

Abstract Selenium is a promising cancer chemoprevention agent. A recent randomized controlled chemoprevention trial found that selenomethionine (SeMet) supplementation for 10 months favorably effected a change in esophageal dysplasia grade among participants who started the trial with mild dysplasia. To further explore the role of SeMet in this trial, we compared gene expression profiles by treatment group using Affymetrix HU 133A chips in before/after supplementation paired normal esophageal biopsies from a subset of 29 trial participants, 16 who received SeMet, and 13 who received placebo. Using P < 0.001 as a cutoff, 11 differentially expressed genes were found in the SeMet supplementation group but these genes did not include either known selenoprotein genes or genes previously shown to be modulated by selenium treatment. Because the number of differentially expressed genes (n = 11) was less than expected by chance (n = 18), we concluded that SeMet supplementation had no measurable effect on gene expression in the normal squamous esophagus of these subjects with dysplasia. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1046-7)